Kincell Bio has successfully closed a $22 million funding round to scale its personalized cell therapy manufacturing services. The investment was led by NewSpring Capital, through its dedicated healthcare fund NewSpring Healthcare, alongside continued support from Kineticos Life Sciences, an early backer of the company.
Based in the U.S., Kincell Bio is a next-generation contract development and manufacturing organization (CDMO) focused on delivering advanced cell therapies. This latest funding milestone underscores its growing influence in the biotech landscape, especially as demand accelerates for fast, flexible, and reliable manufacturing solutions in the cell and gene therapy sector.
The fresh capital will allow Kincell Bio to expand its cGMP manufacturing footprint and enhance its process development capabilities. The company aims to deepen its support for emerging cell therapy ventures, offering end-to-end solutions that span early-stage clinical trials through to commercial launch.
At the heart of Kincell Bio’s offering is a tailored, expert-driven platform that helps biotech innovators move quickly without sacrificing quality. With rapid project timelines and a hands-on approach, the company positions itself as a trusted partner for startups navigating the complexities of cell therapy production.
Alongside the funding news, Kincell Bio also announced a strategic board appointment. Pete Buzy, the former President and CEO of Catalent Cell & Gene Therapy, has joined the board of directors. His addition brings a wealth of sector expertise and operational insight to the company at a pivotal time in its growth.
Kincell Bio CEO Mark R. Bamforth welcomed the developments, stating that the partnership with NewSpring and Buzy marks a major step forward. “With their deep sector knowledge and shared commitment to innovation, we’re well-positioned to continue scaling our operations and delivering high-quality, scalable solutions to our partners in the cell therapy space.”
